Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benigno Rodriguez

Showing results (71-80 of 137) with videos related to

Pageof 14
Sort By:
AIDS (London, England)|July 25, 2012
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine careRobert C Kalayjian, Bryan Lau, Rhoderick N Mechekano, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2016
Reply to Barrett, et alMichael L Freeman, Joseph C Mudd, Carey L Shive, et al.
AIDS (London, England)|September 10, 2003
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapyPeter W Hunt, Steven G Deeks, Benigno Rodriguez, et al.
The Journal of Infectious Diseases|November 17, 2006
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138Michael M Lederman, Laura Smeaton, Kim Y Smith, et al.
The Journal of Infectious Diseases|August 20, 2016
During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV TherapyLenche Kostadinova, Carey L Shive, Chelsey Judge, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 19, 2016
Poorly Controlled HIV Infection: An Independent Risk Factor for Liver FibrosisH Nina Kim, Robin Nance, Stephen Van Rompaey, et al.
Plos One|February 1, 2012
Interferon-alpha administration enhances CD8+ T cell activation in HIV infectionMaura Manion, Benigno Rodriguez, Kathleen Medvik, et al.
AIDS Care|December 24, 2016
Identifying HIV care enrollees at-risk for cannabis use disorderBryan Hartzler, Beatriz H Carlini, Howard Newville, et al.
AIDS and Behavior|June 15, 2017
Influence of Substance Use Disorders on 2-Year HIV Care Retention in the United StatesBryan Hartzler, Julia C Dombrowski, Jason R Williams, et al.
Plos One|December 25, 2013
Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabineNicholas T Funderburg, Adriana Andrade, Ellen S Chan, et al.
Pageof 14

Showing results (71-80 of 137) with videos related to

Sort By:
Pageof 14
AIDS (London, England)|July 25, 2012
Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine careRobert C Kalayjian, Bryan Lau, Rhoderick N Mechekano, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 23, 2016
Reply to Barrett, et alMichael L Freeman, Joseph C Mudd, Carey L Shive, et al.
AIDS (London, England)|September 10, 2003
Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapyPeter W Hunt, Steven G Deeks, Benigno Rodriguez, et al.
The Journal of Infectious Diseases|November 17, 2006
Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138Michael M Lederman, Laura Smeaton, Kim Y Smith, et al.
The Journal of Infectious Diseases|August 20, 2016
During Hepatitis C Virus (HCV) Infection and HCV-HIV Coinfection, an Elevated Plasma Level of Autotaxin Is Associated With Lysophosphatidic Acid and Markers of Immune Activation That Normalize During Interferon-Free HCV TherapyLenche Kostadinova, Carey L Shive, Chelsey Judge, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 19, 2016
Poorly Controlled HIV Infection: An Independent Risk Factor for Liver FibrosisH Nina Kim, Robin Nance, Stephen Van Rompaey, et al.
Plos One|February 1, 2012
Interferon-alpha administration enhances CD8+ T cell activation in HIV infectionMaura Manion, Benigno Rodriguez, Kathleen Medvik, et al.
AIDS Care|December 24, 2016
Identifying HIV care enrollees at-risk for cannabis use disorderBryan Hartzler, Beatriz H Carlini, Howard Newville, et al.
AIDS and Behavior|June 15, 2017
Influence of Substance Use Disorders on 2-Year HIV Care Retention in the United StatesBryan Hartzler, Julia C Dombrowski, Jason R Williams, et al.
Plos One|December 25, 2013
Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabineNicholas T Funderburg, Adriana Andrade, Ellen S Chan, et al.
Pageof 14